The researches find that the Immune Booster have shone a spotlight on a drug already approved for the treatment or prevention of respiratory tract infections, wheeze, and asthma in several European Union countries. The oral cocktail; known as Broncho Vaxom; is taken for 10 consecutive days in each of 3 consecutive months. The drug has not been approve in the United States.
The Immune Booster
Until now; bacterial lysate “was seen as an alternative medicine. Not everyone took it seriously;” de Boer told Medscape Medical News. But results from the two meta-analyses one from the Netherlands and the other from Poland show that bacterial lysate has a significant preventative effect on respiratory disease in children. Both studies are present here at the European Academy of Allergy and Clinical Immunology 2019 Congress.
Bacterial lysate is a collection of inactive extracts from pathogenic respiratory bacteria. The bacteria are heated up to break down the cellular structure but not the protein. Once in the gut; the bacteria activate dendritic cells, which increases immune modulation, stimulates antibody production; and shows evidence of Th1/Th2 cytokine balance, ultimately providing protection against airway pathogens.
Pathogenic respiratory bacteria
Immunobooster on a regular basis when I do not detect any serious immune deficiency in a child;” said investigator Wojciech Feleszko, MD, PhD, from the Medical University of Warsaw in Poland. “They don’t believe it’s a magic bullet;” he told Medscape Medical News, but “it causes an immunoregulatory effect and a dampened allergic response.”
In the 6 years Feleszko has been prescribing bacterial lysate, he has seen no adverse effects. And “young asthmatics taking these products show lower exacerbations” consistently; he reported. In the Dutch meta-analysis, de Boer and her colleagues identified 24 studies that reported the effectiveness of the drug as an add-on therapy for the prevention of respiratory tract infections after a systematic literature review in English.
Increases serum IL-10
They found that asthma exacerbations were significantly lower in youth 6 to 18 years of age after treatment with bacterial lysate than with placebo (mean difference, –0.86; P < .00001). In addition, there was a 23% reduction in COPD exacerbations in the study cohort (relative risk [RR], 0.77; P = .0002).
“They think the results in children are very promising, and it could also be very effective for COPD,” de Boer said. The team also determined that bacterial lysate decreases human interleukin (IL)-4 and increases serum IL-10, IFN gamma, and NKT CD4+ cells, all of which are immunologically beneficial for respiratory disease.
Currently recruiting patients
Most studies of bacterial lysate are under powered, but all show that it improves the incidence of respiratory events, de Boer pointed out. Her team is currently recruiting patients for a trial to look at how bacterial lysate can help adults with respiratory disease, and they plan to monitor microbiome data. “This would be the first study with more insight into adult asthma,” she said.